Abstract:Objective To investigate the anti-proliferative and apoptosis effects induced by Honokiol(HNK)and Bortezomib on KM3 human multiple myeloma cell line in vitro.Methods Samples were divided into the control group and the experimental group,and the latter was further subdivided into the HNK treatment group(group B,C,D,E,F,G at respective concentrations of 4,6,8,10,12,15 μg /mL),the Bortezomib treatment group(group H,I,J at respective concentration of 5,10,20 μg /mL),and the combined treatment group(group K,L,M with HNK 4 μg/mL + Bortezomib 5 ng/mL,HNK4 μg/mL + Bortezomib 10 ng /mL and HNK4 μg/mL + Bortezomib 20 ng/mL,respectively).MTT colorimetric assay were performed to assess cell proliferation and cell apoptosis was determined by PI and Annexin V fluorescent staining on flow cytometry.Results Honokiol,at concentrations between 4-15 μg/mL,showed significant inhibiting effect on KM3 cell proliferation.At 24 h,48 h,and 72 h,the inhibition rate rose from 20.38%,27.45% and 44.94% to 80.54%,89.99% and 90.91%,respectively.There were significant differences among different groups,or at different time points.The inhibition rates of Honokiol on KM3 cells at 48 h in H,I,J,K,L,M were 3.13%,36.22%,53.99%,52.68%,69.99%,78.53%,respectively.There were considerable differences between K and H,L and I,or M and J(P0.05).Apoptosis rate of KM3 cells in B,C,E at 24h and 48 h were 6.92%、16.15%、60.70% and 18.84%、37.21%、86.07%,respectively.There were significant differences in apoptosis among different groups at the same time point(P0.05).Apoptosis rate of KM3 cells in H and I group were 9.27% and 17.87% at 24 h,11.92% and 53.51% at 48 h.Statistical differences were found in apoptosis between H and I group(P0.05).Apoptosis rates of KM3 cells in K and L group were 15.75% and 22.18% at 24h,35.96% and 74.70% at 48 h.The apoptosis rates in K and L group were significantly higher than H and I group(P0.05).Conclusion Honokiol and Bortezomib can inhibit the proliferation of KM3 cells and induce cell apoptosis,moreover,the combination of Honokiol and Bortezomib can increase the apoptosis rates and enhance cytotoxic activity of KM3 cells.

Honokiol Induces Paraptosis And Apoptosis And Exhibits Schedule-Dependent Synergy In Combination With Imatinib In Human Leukemia Cells

Honokiol Induces Caspase-Independent Paraptosis Via Reactive Oxygen Species Production That is Accompanied by Apoptosis in Leukemia Cells

Honokiol Induces Apoptosis and Autophagy Via the ROS/ERK1/2 Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo.

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.

Mechanism of Apoptotic Induction on T24 Cells by Honokiol and Its Synergistic Anticancer Effect in Combination with Hydroxycamptothecin

Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop.

Honokiol Induces Ferroptosis In Colon Cancer Cells By Regulating Gpx4 Activity

Involvement of P38 Mitogen-Activated Protein Kinase Pathway in Honokiol-Induced Apoptosis in A Human Hepatoma Cell Line (Hepg2)

Effects of Honokiol and Bortezomib on Proliferation and Apoptosis in Myeloma KM3 Cells

PUB045 Anti-Tumor Effect of Honokiol in Lung Squamous Cell Carcinoma

Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.

Synergistic Effect of Honokiol and 5‐fluorouracil on Apoptosis of Oral Squamous Cell Carcinoma Cells

Cyclophilin D Modulates Cell Death Transition from Early Apoptosis to Programmed Necrosis Induced by Honokiol

Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells.

Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway

Synergistic Effect of HMGB1 Knockdown and Cordycepin in the K562 Human Chronic Myeloid Leukemia Cell Line.

Synergistic Antitumor Effects of Liposomal Honokiol Combined with Adriamycin in Breast Cancer Models.

Anticancer Effects of Honokiol Via Mitochondrial Dysfunction Are Strongly Enhanced by the Mitochondria-Targeting Carrier Berberine

Honokiol Mediates the Apoptosis of Human Cervical Carcinoma Hela Cells by Regulating P38 Signal Pathway